Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global PD-1 and PD-L1 Inhibitors Market Overview
3.1 Global PD-1 and PD-L1 Inhibitors Market Historical Value (2017-2024)
3.2 Global PD-1 and PD-L1 Inhibitors Market Forecast Value (2024-2032)
4 Global PD-1 and PD-L1 Inhibitors Market Landscape
4.1 Global PD-1 and PD-L1 Inhibitors Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global PD-1 and PD-L1 Inhibitors Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global PD-1 and PD-L1 Inhibitors Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global PD-1 and PD-L1 Inhibitors Market Segmentation
6.1 Global PD-1 and PD-L1 Inhibitors Market by Type
6.1.1 Market Overview
6.1.2 PD-1 Inhibitors
6.1.3 PD-L1 Inhibitors
6.2 Global PD-1 and PD-L1 Inhibitors Market by Applications
6.2.1 Market Overview
6.2.2 Hodgkin’s Lymphoma
6.2.3 Kidney Cancer
6.2.4 Melanoma
6.2.5 Non-Small Cell Lung Cancer
6.2.6 Other Applications
6.3 Global PD-1 and PD-L1 Inhibitors Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.4 Global PD-1 and PD-L1 Inhibitors Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America PD-1 and PD-L1 Inhibitors Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe PD-1 and PD-L1 Inhibitors Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific PD-1 and PD-L1 Inhibitors Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America PD-1 and PD-L1 Inhibitors Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa PD-1 and PD-L1 Inhibitors Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Supplier Landscape
16.1 Bristol Myers Squibb
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisition
16.1.5 Certifications
16.2 Merck & Co., Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisition
16.2.5 Certifications
16.3 Roche
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisition
16.3.5 Certifications
16.4 AstraZeneca
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisition
16.4.5 Certifications
16.5 Pfizer, Inc.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisition
16.5.5 Certifications
16.6 Eli Lilly and Company
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisition
16.6.5 Certifications
16.7 Sanofi
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisition
16.7.5 Certifications
16.8 Regeneron Pharmaceuticals
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisition
16.8.5 Certifications
16.9 Novartis AG
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisition
16.9.5 Certifications
16.10 BIOCAD
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisition
16.10.5 Certifications
16.11 Cipla Limited
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisition
16.11.5 Certifications
16.12 MacroGenics, Inc.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisition
16.12.5 Certifications
16.13 Innovent Biologics
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisition
16.13.5 Certifications
16.14 Jiangsu Hengrui Medicine Co., Ltd.
16.14.1 Financial Analysis
16.14.2 Product Portfolio
16.14.3 Demographic Reach and Achievements
16.14.4 Mergers and Acquisition
16.14.5 Certifications
16.15 Mirati Therapeutics
16.15.1 Financial Analysis
16.15.2 Product Portfolio
16.15.3 Demographic Reach and Achievements
16.15.4 Mergers and Acquisition
16.15.5 Certifications
17 Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 45.8 billion in 2023, driven by rising prevalence of cancer cases across the globe.
The market is anticipated to grow at a CAGR of 17.96% during the forecast period of 2024-2032, likely to reach a market value of USD 202.5 billion by 2032.
The market demand is driven by increased demand for efficient cancer treatment solutions along with rising geriatric population and increased investments by the governments to support the healthcare and pharmaceutical industries.
The current market trend involves the advent of new drugs to treat rare cancer types. In March 2023, the FDA approved an intravenous drug called Zynyz, developed by Incyte which can be used to treat metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
The market can be divided into PD-1 and PD-L1 inhibitors.
These inhibitors find wide applications in Hodgkin lymphoma, kidney cancer, melanoma, and non-small cell lung cancer, among others.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Bristol Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Pfizer, Inc., Eli Lilly and Company, Sanofi, Regeneron Pharmaceuticals, Novartis AG, BIOCAD, Cipla Limited, MacroGenics, Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Ltd. and Mirati Therapeutics.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.